MGNX — MacroGenics, Inc.
Is MGNX overbought or oversold? Here is the current MarketMoodz read.
MacroGenics, Inc. (MGNX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $2.17. The rating moved from Neutral to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$2.17
- Last changeMoved from Neutral to Oversold on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
MacroGenics, Inc. is a clinical-stage biopharma where valuation is primarily driven by upcoming clinical milestones, partnership opportunities, and financing choices. The company’s financial health and near-term outlook hinge on the timing and outcomes of program readouts and the ability to secure non-dilutive or reasonably priced capital. Current market conditions show investor preference for large-cap pharma and defensives, which can pressure smaller biotech names and limit near-term upside absent positive catalysts. Upside scenarios include favorable trial data or deal activity that attracts acquirers or partners; downside scenarios involve clinical setbacks, regulatory delays, or dilutive financings that materially compress equity value. Social sentiment and EDGAR-derived visibility are limited, increasing reliance on clinical and corporate announcements for directional moves.
Key factors
- Pipeline- and clinical-readout driven business model creates binary upside from positive trial results or licensing/M&A interest
- Limited publicly-available evidence of robust, diversified revenue streams increases sensitivity to financing and milestone timing
- Sector-wide flows favoring large-cap pharma may reduce small-cap biotech investor appetite in the near term
- Convertible-debt and broader capital-markets dynamics in the diagnostics/biotech space increase probability of dilutive or expensive financing
- Low absolute share price implies limited liquidity and higher volatility, which can amplify moves around news or earnings
Risks
- Negative or delayed clinical trial readouts that directly impact valuation and partner interest
- Need for dilutive equity or expensive debt financing to fund operations and trials, compressing shareholder value
- Regulatory setbacks or longer-than-expected approval timelines for key programs
- Competition from larger pharmaceutical companies and alternative therapeutic approaches that could reduce addressable market
- Low trading liquidity and heightened volatility leading to outsized price moves unrelated to fundamentals
- Sector-wide sentiment shifts (rotation to large-cap defensives) reducing near-term investor interest
See today's live rating, score and targets
Members see the live hourly rating for MGNX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.